Barilla G. e R. Fratelli- Societa per Azioni (”Barilla Group”), owner of the famous BARILLA brand, unsuccessfully opposed an application to register the words “Barilla Dumpling” as a trade mark in respect of “Asian-style restaurant services” in New Zealand. This case demonstrates the necessity of accurate pleadings in trade mark opposition and revocation proceedings in New Zealand.
Four Peptides, No Problem: Neoantigen Patent Stands Strong in Opposition Proceedings
Delegate Wagg of the Australian Patent Office has ruled in favour of Dana-Farber Cancer Institute, Inc. and The General Hospital Corporation (the Applicants) in “straw person” opposition proceedings brought by QIP Nominees Pty Ltd (QIP), a company within the QANTM intellectual property group.
Pearce IP BioBlast® for the week ending 15 November 2024
Aflibercept 15 November 2024 | EU | Sandoz Aflibercept Biosimilars EU Approved & Formycon/Klinge Biosims...
Pearce IP BioBlast® for the week ending 08 November 2024
Aflibercept 30 October 2024 | US | Amgen Launches Aflibercept in the US, Prepares to Launch Ustekinumab &...
Pearce IP BioBlast® for the week ending 01 November 2024
Benralizumab 28 October 2024 | EU | New Indication Alert: AstraZeneca’s Fasenra® (Benralizumab) EU-Approved for EGPA...
Pearce IP BioBlast® for the week ending 25 October 2024
Aflibercept 23 October 2024 | Biocon Switching Study for Aflibercept Confirms Safety & Efficacy On 23 October...
Nose Dive – ResMed’s Opposition Gets a Rude Awakening
Barilla G. e R. Fratelli- Societa per Azioni (”Barilla Group”), owner of the famous BARILLA brand, unsuccessfully opposed an application to register the words “Barilla Dumpling” as a trade mark in respect of “Asian-style restaurant services” in New Zealand. This case demonstrates the necessity of accurate pleadings in trade mark opposition and revocation proceedings in New Zealand.
Pearce IP BioBlast® for the week ending 18 October 2024
Aflibercept 18 October 2024 | Regeneron Announces 3-Year Results for High Dose Eylea® (Aflibercept) On 18 October...
Pearce IP BioBlast® for the fortnight ending 11 October 2024
Aflibercept 8 October 2024 | AU | Bayer’s High Dose Eylea® (Aflibercept) PFS Approved in Australia On 8 October 2024,...
Soft Close, Hard Lessons: Full Court Reinforces Purposive Construction of Patent Claims and the Disclosure Requirements for Divisional Patents
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Insert Appeal, Pull Lever, Repeat: Aristocrat Deals itself another Hand in Ongoing Dispute over Electronic Gaming Machine Patents
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Rough Ride: EIS Gets a Tough Massage from LELO
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Pearce IP BioBlast® for the week ending 27 September 2024
Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
Pearce IP BioBlast® for the week ending 20 September 2024
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
Pearce IP BioBlast® for the week ending 13 September 2024
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Pearce IP BioBlast® for the fortnight ending 06 September 2024
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...